Pricing Log in Create free account
Friday 6 November 2026 Export TAK’s income statement to Excel — free account

Takeda Pharmaceutical Co.

TAK Healthcare Drug Manufacturers Specialty & Generic

Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.

Revenue
+1.71%
EPS
−4.35%
Free cash flow
+54.9%
Total debt
−7.28%

Quarter to September 2026, against a year earlier

21.25 0.19 +0.90%
Market cap
$67.7B
P/E
32.0×
Fwd P/E
—
Dividend yield
1.45%
F-score
4/9
Altman Z
1.03
Beneish M
−2.65
Dividend safety
25/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Takeda Pharmaceutical Co. (TAK) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Takeda Pharmaceutical Co. (TAK) trades at a EV/Sales of 3.1×. Over the past ten years it has ranged from 1.9× (June 2019) to 5.0× (July 2019); the current reading is higher than 82% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2026 2.8× 10.89%
FY2025 2.6× 3.00%
FY2024 2.5× (7.04%)
FY2023 2.7× 11.95%
FY2022 2.4× (21.48%)
FY2021 3.0× 4.24%
FY2020 2.9× 27.20%
FY2019 2.3× (17.90%)
FY2018 2.8× 10.85%
FY2017 2.5× 6.87%

Quarterly newest first

Period EV/Sales Change
Jun 2026 2.6× 2.00%
Jun 2025 2.6× 7.21%
Jun 2024 2.4× (3.51%)
Mar 2024 2.5× (0.93%)
25 more quarters

Against its own ten years

Low 1.9× High 5.0×
Ten-year median 2.5×
Current reading's percentile 80

EV/Sales against peers

Company EV/Sales
VTRS Viatris Inc. compare 2.3×
HLN Haleon PLC Sponsored ADR compare 2.9×
ELAN Elanco Animal Health Incorporated compare 3.0×
TAK Takeda Pharmaceutical Co. 3.1×
TEVA Teva Pharmaceutical Industries Ltd. compare 3.6×
RDY Dr. Reddy's Laboratories Ltd compare 3.6×
NBIX Neurocrine Biosciences, Inc. compare 4.4×
ZTS Zoetis Inc. compare 4.5×
UTHR United Therapeutics Corporation compare 6.6×
Drug Manufacturers Specialty & Generic industry median 2.9×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on TAK